Enpro Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Enpro Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $381.40M | Aug 2, 2019 |
| FY2018 | Sep 30, 2018 | $388.20M | Aug 2, 2019 |
| FY2018 | Jun 30, 2018 | $393.60M | Aug 2, 2019 |
| FY2018 | Mar 31, 2018 | $368.80M | Aug 2, 2019 |
| FY2018 | Dec 31, 2017 | $362.50M | Aug 2, 2019 |
| FY2018 | Sep 30, 2017 | $343.70M | Aug 2, 2019 |
| FY2018 | Jun 30, 2017 | $307.60M | Aug 2, 2019 |
| FY2018 | Mar 31, 2017 | $295.80M | Aug 2, 2019 |
| FY2018 | Dec 31, 2016 | $1.19B | Aug 2, 2019 |
| FY2015 | Dec 31, 2015 | $3.60M | Feb 26, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.05B | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.06B | Feb 21, 2025 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 21, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $362.50M | Feb 26, 2018 |
| FY2016 | Dec 31, 2016 | $286.90M | Feb 22, 2017 |
| FY2017 | Sep 30, 2016 | $343.70M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $307.60M | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $295.80M | Feb 26, 2018 |
| FY2017 | Dec 31, 2015 | $286.90M | Feb 26, 2018 |
| FY2017 | Sep 30, 2015 | $292.70M | Feb 26, 2018 |
| FY2017 | Jun 30, 2015 | $313.20M | Feb 26, 2018 |
| FY2017 | Mar 31, 2015 | $294.90M | Feb 26, 2018 |
| FY2015 | Dec 31, 2014 | $316.40M | Feb 26, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $487.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $444.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $426.80M | Feb 19, 2026 |
| FY2022 | Dec 31, 2022 | $105.50M | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | $110.80M | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | $112.30M | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | $94.70M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $78.70M | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | $83.70M | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | $87.20M | Mar 1, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $72.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $22.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $205.10M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $177.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $177.60M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $2.80M | Mar 11, 2020 |
| FY2019 | Sep 30, 2019 | ($1.50M) | Mar 11, 2020 |
| FY2019 | Jun 30, 2019 | $23.90M | Mar 11, 2020 |
| FY2019 | Mar 31, 2019 | $13.10M | Mar 11, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $161.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $142.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $76.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $72.20M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $65.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $29.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $56.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $85.80M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $70.20M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($2.50M) | Aug 2, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $10.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $9.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $10.10M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $9.80M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $9.40M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $20.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $22.90M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $24.50M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $28.90M | Aug 2, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $323.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $296.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $284.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $282.80M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $260.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $230.20M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $314.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $311.60M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $298.30M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $302.70M | Aug 2, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $29.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $33.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $29.40M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $14.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $13.40M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $21.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $36.10M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $30.30M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $35.80M | Aug 2, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.66B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.49B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.50B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.65B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.97B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.08B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.04B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.72B | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $1.89B | Aug 2, 2019 |
| FY2017 | Dec 31, 2016 | $1.55B | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.07B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.23B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.65B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $956.70M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.12B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $858.10M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $983.30M | Aug 2, 2019 |
| FY2017 | Dec 31, 2016 | $1.19B | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.43B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.41B | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $1.40B | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $1.27B | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $1.08B | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $896.60M | Mar 1, 2023 |
| FY2019 | Dec 31, 2018 | $857.70M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $902.80M | Aug 2, 2019 |
| FY2018 | Dec 31, 2016 | $358.50M | Aug 2, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $896.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $808.40M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $863.80M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $948.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $605.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $485.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $322.10M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $324.10M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $201.50M | Aug 2, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.13B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.13B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $953.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $794.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $632.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $603.30M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $604.40M | Aug 2, 2019 |
| FY2017 | Dec 31, 2016 | $84.00M | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $236.30M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $369.80M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $334.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $338.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $229.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $121.20M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $129.60M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $189.30M | Aug 2, 2019 |
| FY2018 | Dec 31, 2016 | $111.50M | Aug 2, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $655.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $640.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $646.80M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $790.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $976.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $491.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $629.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $464.90M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $618.50M | Aug 2, 2019 |
| FY2017 | Dec 31, 2016 | $425.00M | Feb 26, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 19, 2026 |
| FY2022 | Dec 31, 2022 | 6.11M | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | 1.29M | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | 1.65M | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | 810,000 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 4.97M | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | 1.36M | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | 1.43M | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 19, 2026 |
| FY2022 | Dec 31, 2022 | 6.11M | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | 1.29M | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | 1.65M | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | 810,000 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 4.97M | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | 1.35M | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | 1.42M | Mar 1, 2023 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $25.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $24.30M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $23.40M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $22.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $21.70M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $20.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $20.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $19.00M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $18.10M | Aug 2, 2019 |